Clinical Trial

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.
Protocol Amendment History 33 amendments
This ClinicalTrials.gov record has been amended 33 times since 2017-12-05; most recent amendment 2026-01-13.
Status change: Recruiting → Active, Not Recruiting 2022-06-08
Status change: Not Yet Recruiting → Recruiting 2018-02-19
Trial Details
NCT Number NCT03367702
Lead Sponsor NRG Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Stage II Prostate Adenocarcinoma AJCC v7
Enrollment 692 participants
Start Date 2018-02-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-15